Estrogens are gonadal steroid hormones that are present in the circulation of both males and females and that can no longer be considered within the strict confines of reproductive function. In fact, the bone, the cardiovascular system, and extrahypothalamic regions of the brain are now well-established targets of estrogens. Among the numerous aspects of brain function regulated by estrogens are their effects on mood, cognitive function, and neuronal viability. Here, we review the supporting evidence for estrogens as neuroprotective agents and summarize the various mechanisms that may be involved in this effect, focusing particularly on the mitochondria as an important target. On the basis of this evidence, we discuss the clinical applicability of estrogens in treating various age-related disorders, including Alzheimer disease and stroke, and identify the caveats that must be considered.
BishopJ, SimpkinsJW. Estradiol treatment increases viability of glioma and neuroblastoma cells in vitro. Mol Cell Neurosci5: 303–308, 1994.
4.
GreenPS, SimpkinsJW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci18: 347–358, 2000.
5.
GreenPS, GridleyKE, SimpkinsJW. Estradiol protects against beta-amyloid (25-35)–induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett218: 165–168, 1996.
6.
GoodmanY, BruceAJ, ChengB, MattsonMP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem66: 1836–1844, 1996.
7.
BehlC, WidmannM, TrappT, HolsboerF. 17-Beta estradiol protects neurons from oxidative stress–induced cell death in vitro. Biochem Biophys Res Commun216: 473–482, 1995.
8.
ZaulyanovLL, GreenPS, SimpkinsJW. Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an in vitro model for assessment of the neuroprotective effects of estrogens. Cell Mol Neurobiol19: 705–718, 1999.
ReganRF, GuoY. Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain Res764: 133–140, 1997.
11.
WilsonME, DubaiDB, WisePM. Estradiol protects against injury-induced cell death in cortical explant cultures: a role for estrogen receptors. Brain Res873: 235–242, 2000.
WangJ, GreenPS, SimpkinsJW. Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J Neurochem77: 804–811, 2001.
14.
De GirolamoLA, HargreavesAJ, BillettEE. Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. J Neurochem76: 650–660, 2001.
SimpkinsJW, RajakumarG, ZhangYQ, SimpkinsCE, GreenwaldD, YuCJ, BodorN, DayAL. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg87: 724–730, 1997.
18.
HeZ, HeYJ, DayAL, SimpkinsJW. Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: perfusion-dependent and-independent mechanisms. J Neurol Sci193: 79–87, 2002.
MendelowitschA, RitzMF, RosJ, LangemannH, GratzlO. 17β-Estradiol reduces cortical lesion size in the glutamate excitotoxicity model by enhancing extracellular lactate: a new neuroprotective pathway. Brain Res901: 230–236, 2001.
22.
CulmseeC, VedderH, RavatiA, JunkerV, OttoD, AhlemeyerB, KriegJC, KrieglsteinJ. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab19: 1263–1269, 1999.
23.
ChenJ, XuW, JiangH. 17β-Estradiol protects neurons from ischemic damage and attenuates accumulation of extracellular excitatory amino acids. Anesth Analg92: 1520–1523, 2001.
24.
WisePM, DubaiDB, WilsonME, RauSW, BottnerM, RosewellKL. Estradiol is a protective factor in the adult and aging brain: understanding of mechanisms derived from in vivo and in vitro studies. Brain Res Brain Res Rev37: 313–319, 2001.
25.
ToungTK, HumPD, TraystmanRJ, SieberFE. Estrogen decreases infarct size after temporary focal ischemia in a genetic model of type 1 diabetes mellitus. Stroke31: 2701–2706, 2000.
26.
CarswellHV, AndersonNH, MortonJJ, McCullochJ, DominiczakAF, MacraeIM. Investigation of estrogen status and increased stroke sensitivity on cerebral blood flow after a focal ischemic insult. J Cereb Blood Flow Metab20: 931–936, 2000.
27.
YangSH, HeZ, WuSS, HeYJ, CutrightJ, MillardWJ, DayAL, SimpkinsJW. 17-β Estradiol can reduce secondary ischemic damage and mortality of subarachnoid hemorrhage. J Cereb Blood Flow Metab21: 174–181, 2001.
28.
ToungTJ, TraystmanRJ, HumPD. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke29: 1666–1670, 1998.
29.
HawkT, ZhangYQ, RajakumarG, DayAL, SimpkinsJW. Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res796: 296–298, 1998.
30.
GreeneG, GilnaP, WaterfieldM, BakerA, HortY, ShineJ. Sequence and expression of human estrogen receptor complementary DNA. Science231: 1150–1154, 1986.
31.
KuiperGG, EnmarkE, Pelto-HuikkoM, NilssonS, GustafssonJA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A93: 5925–5930, 1996.
32.
OgawaS, InoueS, WatanabeT, HiroiH, OrimoA, HosoiT, OuchiY, MuramatsuM. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun243: 122–126, 1998.
33.
MosselmanS, PolmanJ, DijkemaR. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett392: 49–53, 1996.
34.
EvansRM. The steroid and thyroid hormone receptor superfamily. Science240: 889–895, 1988.
35.
LandersJP, SpelsbergTC. New concepts in steroid hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit Rev Eukaryot Gene Expr2: 19–63, 1992.
36.
KuiperGG, CarlssonB, GrandienK, EnmarkE, HaggbladJ, NilssonS, GustafssonJA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology138: 863–870, 1997.
37.
ShughrueP, ScrimoP, LaneM, AskewR, MerchenthalerI. The distribution of estrogen receptor-beta mRNA in forebrain regions of the estrogen receptor-alpha knockout mouse. Endocrinology138: 5649–5652, 1997.
38.
OsterlundM, KuiperGG, GustafssonJA, HurdYL. Differential distribution and regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res Mol Brain Res54: 175–180, 1998.
39.
LiX, SchwartzPE, RissmanEF. Distribution of estrogen receptor-beta-like immunoreactivity in rat forebrain. Neuroendocrinology66: 63–67, 1997.
40.
DonCarlosL. Estrogen receptor β (ER-β) mRNA in developing rat forebrain. Soc Neurosci Abstracts23: 343, 1997.
41.
ChowenJA, Torres-AlemanI, Garcia-SeguraLM. Trophic effects of estradiol on fetal rat hypothalamic neurons. Neuroendocrinology56: 895–901, 1992.
42.
PatroneC, AnderssonS, KorhonenL, LindholmD. Estrogen receptor-dependent regulation of sensory neuron survival in developing dorsal root ganglion. Proc Natl Acad Sci U S A96: 10905–10910, 1999.
43.
GollapudiL, OblingerMM. Stable transfection of PC12 cells with estrogen receptor (ERalpha): protective effects of estrogen on cell survival after serum deprivation. J Neurosci Res56: 99–108, 1999.
44.
SawadaH, IbiM, KiharaT, UrushitaniM, HondaK, NakanishiM, AkaikeA, ShimohamaS. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. Faseb J14: 1202–1214, 2000.
45.
CouseJF, CurtisSW, WashburnTF, LindzeyJ, GoldingTS, LubahnDB, SmithiesO, KorachKS. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol9: 1441–1454, 1995.
46.
McCulloughLD, AlkayedNJ, TraystmanRJ, WilliamsMJ, HumPD. Postishemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke32: 796–802, 2001.
47.
SugoN, AlkayedNJ, BlizzardKK, McCulloughLD, TraystmanRJ, CrainBJ, KorachKS, HumPD. Estrogen protects ischemic brain of estrogen receptor-alpha or -beta knockout mice. Soc Neurosci Abstracts No 437.13, 2001.
48.
MooreJT, McKeeDD, Slentz-KeslerK, MooreLB, JonesSA, HomeEL, SuJL, KliewerSA, LehmannJM, WillsonTM. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun247: 75–78, 1998.
NordellVL, ScarboroughMM, BuchananAK, SohrabjiF. Differential effects of estrogen in the injured forebrain of young adult and reproductive senescent animals. Neurobiol Aging24: 733–743, 2003.
51.
JezierskiMK, SohrabjiF. Neurotrophin expression in the reproductively senescent forebrain is refractory to estrogen stimulation. Neurobiol Aging22: 309–319, 2001.
52.
AnuradhaP, KhanSM, KarthikeyanN, ThampanRV. The non-activated estrogen receptor (naER) of the goat uterus is a tyrosine kinase. Arch Biochem Biophys309: 195–204, 1994.
53.
PappasTC, GametchuB, WatsonCS. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. Faseb J9: 404–410, 1995.
54.
PietrasRJ, SzegoCM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature265: 69–72, 1977.
55.
WatsonCS, PappasTC, GametchuB. The other estrogen receptor in the plasma membrane: implications for the actions of environmental estrogens. Environ Health Perspect103(Suppl 7):41–50, 1995.
56.
Toran-AllerandCD, GuanX, MacLuskyNJ, HorvathTL, DianoS, SinghM, ConnollyESJr., NethrapalliIS, TinnikovAA. ER-X: a novel, plasma membrane–associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci22: 8391–8401, 2002.
57.
SinghM, SetaloGJr., GuanX, WarrenM, Toran-AllerandC. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci19: 1179–1188, 1999.
58.
SinghM, SetaloGJr., GuanX, FrailDE, Toran-AllerandCD. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice. J Neurosci20: 1694–1700, 2000.
59.
SinghM. Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex. Endocrine14: 407–415, 2001.
60.
SingerCA, Figueroa-MasotXA, BatchelorRH, DorsaDM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci19: 2455–2463, 1999.
61.
ZhangL, RubinowDR, XaingG, LiBS, ChangYH, MaricD, BarkerJL, MaW. Estrogen protects against beta-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. Neuroreport12: 1919–1923, 2001.
HondaK, ShimohamaS, SawadaH, KiharaT, NakamizoT, ShibasakiH, AkaikeA. Nongenomic antiapoptotic signal transduction by estrogen in cultured cortical neurons. J Neurosci Res64: 466–475, 2001.
64.
CarlstromL, KeZJ, UnnerstallJR, CohenRS, PandeySC. Estrogen modulation of the cyclic AMP response element-binding protein pathway: effects of long-term and acute treatments. Neuroendocrinology74: 227–243, 2001.
DodelRC, DuY, BalesKR, GaoF, PaulSM. Sodium salicylate and 17beta-estradiol attenuate nuclear transcription factor NF-kappaB translocation in cultured rat astroglial cultures following exposure to amyloid A beta(1–40) and lipopolysaccharides. J Neurochem73: 1453–1460, 1999.
67.
SimpkinsJW, YangSH, WenY, SinghM. Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies. Cell Mol Life Sci62: 271–280, 2005
68.
SegarsJH, DriggersPH. Estrogen action and cytoplasmic signaling cascades. Part I: Membrane-associated signaling complexes. Trends Endocrinol Metab13: 349–354, 2002.
69.
Garcia-SeguraLM, AzcoitiaI, DonCarlosLL. Neuroprotection by estradiol. Prog Neurobiol63: 29–60, 2001.
70.
GreenDR, KroemerG. The pathophysiology of mitochondrial cell death. Science305: 626–629, 2004.
71.
DykensJA. Mitochondrial free radical production and the etiology of neurodegenerative disease. In: BealMF, HowellN, Bodis-WollnerI, Eds. Neurodegenerative Diseases: Mitochondria and Free Radicals in Pathogenesis. New York: John Wiley & Sons, pp 29–55, 1997.
72.
SmithMA, NunomuraA, ZhuX, TakedaA, PerryG. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal2: 413–420, 2000.
73.
AlievG, SmithMA, SeyidovD, NealML, LambBT, NunomuraA, GasimovEK, VintersHV, PerryG, LaMannaJC, FriedlandRP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol12: 21–35, 2002.
74.
CottrellDA, IncePG, WardellTM, TumbullDM, JohnsonMA. Accelerated ageing changes in the choroid plexus of a case with multiple mitochondrial DNA deletions. Neuropathol Appl Neurobiol27: 206–214, 2001.
75.
BosettiF, BrizziF, BarogiS, MancusoM, SicilianoG, TendiEA, MurriL, RapoportSI, SolainiG. Cytochrome c oxidase and mitochondrial FIFO-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging23: 371–376, 2002.
76.
GibsonGE, SheuKF, BlassJP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm105: 855–870, 1998.
77.
KishSJ. Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. Ann N Y Acad Sci826: 218–228, 1997.
GhoshSS, SwerdlowRH, MillerSW, SheemanB, ParkerWDJr., DavisRE. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci893: 176–191, 1999.
80.
ShoffnerJM. Oxidative phosphorylation defects and Alzheimer's disease. Neurogenetics1: 13–19, 1997.
81.
DykensJA, WilesME, WrightCD, TowbinKE, DykensEM, PuglieseRG, HodappRM, EvansDW. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated Ca2+ and Na+: implications for neurodegeneration. J Neurochem63: 584–591, 1994.
82.
LemastersJJ, NieminenAL, QianT, TrostLC, HermanB. The mitochondrial permeability transition in toxic, hypoxic and reperfusion injury. Mol Cell Biochem174: 159–165, 1997.
83.
KroemerG, ReedJC. Mitochondrial control of cell death. Nat Med6: 513–519, 2000.
84.
ZouH, HenzelWJ, LiuX, LutschgA, WangX. Apaf-1, a human protein homologous to C. elegans CED-4. participates in cytochrome c-dependent activation of caspase-3. Cell90: 405–413, 1997.
85.
DykensJA. Free radicals and mitochondrial dysfunction in excitotoxicity and neurodegenerative diseases. In: KoliatsosVE, RatanRR, Eds. Cell Death and Diseases of the Nervous System. Totowa. NJ: Humana Press, pp 45–68, 1999.
86.
MurphyAN, FiskumG, BealMF. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab19: 231–245, 1999.
87.
ChanPH. Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia. Neurochem Res29: 1943–1949, 2004.
88.
NilsenJ, Diaz BrintonR. Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci U S A100: 2842–2847, 2003.
89.
WisePM, DubaiDB, WilsonME, RauSW. Estradiol is a neuroprotective factor in in vivo and in vitro models of brain injury. J Neurocytol29: 401–410, 2000.
90.
YangSH, LiuR, PerezEJ, WenY, StevensSMJr., ValenciaT, Brun-ZinkemagelAM, ProkaiL, WillY, DykensJ, KoulenP, SimpkinsJW. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A101: 4130–4135, 2004.
91.
KroemerG. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med3: 614–620, 1997.
92.
ZhengJ, RamirezVD. Purification and identification of an estrogen binding protein from rat brain: oligomycin sensitivity–conferring protein (OSCP), a subunit of mitochondrial F0F1-ATP synthase/ATPase. J Steroid Biochem Mol Biol68: 65–75, 1999.
93.
ZhengJ, RamirezVD. Rapid inhibition of rat brain mitochondrial proton FOF1-ATPase activity by estrogens: comparison with Na+, K+-ATPase of porcine cortex. Eur J Pharmacol368: 95–102, 1999.
94.
WangX, SimpkinsJW, DykensJA, CammarataPR. Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci44: 2067–2075, 2003.
95.
CegelskiL, RiceCV, O'connorRD, CaruanoAL, TochtropGP, CaiZY, CoveyDF, SchaeferJ. Mapping the locations of estradiol and potent neuroprotective analogues in phospholipid bilayers by REDOR NMR. Drug Development Research6: 93–102, 2006.
96.
LiangY, BelfordS, TangF, ProkaiL, SimpkinsJW, HughesJA. Membrane fluidity effects of estratrienes. Brain Res Bull54: 661–668, 2001.
97.
GreenPS, GridleyKE, SimpkinsJW. Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience84: 7–10, 1998.
98.
GridleyKE, GreenPS, SimpkinsJW. Low concentrations of estradiol reduce beta-amyloid (25–35)–induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res778: 158–165, 1997.
99.
DykensJA, SimpkinsJW, WangJ, GordonK. Polycyclic phenols, estrogens and neuroprotection: a proposed mitochondrial mechanism. Exp Gerontol38: 101–107, 2003.
100.
ProkaiL, Prokai-TatraiK, PerjesiP, ZharikovaAD, SimpkinsJW. Quinol-based metabolic cycle for estrogens in rat liver microsomes. Drug Metab Dispos31: 701–704, 2003.
101.
ProkaiL, Prokai-TatraiK, PerjesiP, ZharikovaAD, PerezEJ, LiuR, SimpkinsJW. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci U S A100: 11741–11746, 2003.
102.
DenisovET, DenisovaTG. Handbook of antioxidants: bond dissociation energies, rate constants, activation energies, and enthalpies of reactions. Boca Raton: CRC Press, p 289, 2000.
103.
NilsenJ, ChenS, BrintonRD. Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway. Brain Res930: 216–234, 2002.
104.
MorinC, ZiniR, SimonN, TillementJP. Dehydroepiandrosterone and alpha-estradiol limit the functional alterations of rat brain mitochondria submitted to different experimental stresses. Neuroscience115: 415–424, 2002.
BrintonRD. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem8: 121–133, 2001.
107.
DykensJA. Mitochondrial radical production and mechanisms of oxidative excitotoxicity. In: DaviesKJA, UrsiniF, Eds. The Oxygen Paradox. Padova: Cleup Press, University of Padova, pp 453–467, 1995.
108.
MurphyAN. Ca(2+)-mediated mitochondrial dysfunction and the protective effects of Bcl-2. Ann N Y Acad Sci893: 19–32, 1999.
109.
DykensJA, StoutAK. Assessment of mitochondrial membrane potential in situ using single potentiometric dyes and a novel fluorescence resonance energy transfer technique. Methods Cell Biol65: 285–309, 2001.
GradyD, RubinSM, PetittiDB, FoxCS, BlackD, EttingerB, ErnsterVL, CummingsSR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med117: 1016–1037, 1992.
112.
ZandiPP, CarlsonMC, PlassmanBL, Welsh-BohmerKA, MayerLS, SteffensDC, BreitnerJC. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA288: 2123–2129, 2002.
113.
HendersonV, Paganini-HillA, EmanuelC, DunnM, BuckwalterJ. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol51: 896–900, 1994.
114.
HardingJJ. Estrogens and cataract. Arch Ophthalmol112: 1511, 1994.
115.
FillitH, WeinrebH, Cholst1, LuineV, McEwenB, AmadorR, ZabriskieJ. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology11: 337–345, 1986.
116.
OhkuraT, IsseK, AkazawaK, HamamotoM, YaoiY, HaginoN. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J41: 361–371, 1994.
117.
KawasC, ResnickS, MorrisonA, BrookmeyerR, CorradaM, ZondermanA, BacalC, LingleDD, MetterE. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging [published erratum appears in Neurology 51: 654, 1998]. Neurology48: 1517–1521, 1997.
118.
Paganini-HillA, HendersonV. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol140: 256–261, 1994.
119.
Paganini-HillA, HendersonVW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med156: 2213–2217, 1996.
120.
TangMX, JacobsD, StemY, MarderK, SchofieldP, GurlandB, AndrewsH, MayeuxR. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet348: 429–432, 1996.
121.
SchneiderLS, FarlowMR, HendersonVW, PogodaJM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology46: 1580–1584, 1996.
122.
ShumakerSA, LegaultC, KullerL, RappSR, ThalL, LaneDS, FillitH, StefanickML, HendrixSL, LewisCE, MasakiK, CokerLH. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA291: 2947–2958, 2004.
123.
EspelandMA, RappSR, ShumakerSA, BrunnerR, MansonJE, SherwinBB, HsiaJ, MargolisKL, HoganPE, WallaceR, DaileyM, FreemanR, HaysJ. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA291: 2959–2968, 2004.
124.
Wassertheil-SmollerS, HendrixSL, LimacherM, HeissG, KooperbergC, BairdA, KotchenT, CurbJD, BlackH, RossouwJE, AragakiA, SaffordM, SteinE, LaowattanaS, MysiwWJ. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA289: 2673–2684, 2003.
125.
ShumakerSA, LegaultC, RappSR, ThalL, WallaceRB, OckeneJK, HendrixSL, JonesBN3rd., AssafAR, JacksonRD, KotchenJM, Wassertheil-SmollerS, Wactawski-WendeJ. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA289: 2651–2662, 2003.
126.
RappSR, EspelandMA, ShumakerSA, HendersonVW, BrunnerRL, MansonJE, GassML, StefanickML, LaneDS, HaysJ, JohnsonKC, CokerLH, DaileyM, BowenD. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA289: 2663–2672, 2003.
127.
SinghM, SimpkinsJW. The Future of Hormone Therapy: What basic science and clinical studies teach us. New York: New York Academy of Science, p 261, 2005.
128.
SimpkinsJW, SinghM. Consortium for the Assessment of Research on Progestins and Estrogens (CARPE) Fort Worth, Texas August 1-3, 2003. J Womens Health (Larchmt)13: 1165–1168, 2004.
129.
AlkjaersigN, FletcherAP, de ZieglerD, SteingoldKA, MeldrumDR, JuddHL. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med111: 224–228, 1988.
130.
De LignieresB, BasdevantA, ThomasG, ThalabardJC, Mercier-BodardC, ConardJ, GuyeneTT, MaironN, CorvolP, Guy-GrandB. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab62: 536–541, 1986.
131.
HarmanSM, NaftolinF, BrintonEA, JudelsonDR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative Study: a critical evaluation of the evidence. Ann N Y Acad Sci1052: 43–56, 2005.
132.
PerezE, LiuR, YangSH, CaiZY, CoveyDF, SimpkinsJW. Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Res1038: 216–222, 2005.
133.
GleasonCE, CarlssonCM, JohnsonS, AtwoodC, AsthanaS. Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Ann N Y Acad Sci1052: 93–115, 2005.
